Jarman E R, Perschke K, Montermann E, Herz U, Renz H, Knop J, Reske-Kunz A B
Clinical Research Unit, Department of Dermatology, Johannes Gutenberg-University, Mainz, Germany.
J Allergy Clin Immunol. 2000 May;105(5):967-74. doi: 10.1067/mai.2000.105320.
Hu-PBL-SCID mice generated by the transfer of PBMCs from atopic individuals may provide a physiologic in vivo model for investigating human responses to allergens and potential approaches toward immunotherapy.
This study was undertaken to investigate the functional activity and cytokine profile of human allergen-reactive T lymphocytes isolated from hu-PBL-SCID mice.
PBMCs from allergic individuals were coinjected with allergen into SCID mice. Human lymphocyte migration and phenotype were established by reverse transcription-PCR and immunohistochemistry, IgE levels in sera were determined, and the frequency of allergen-reactive cytokine-producing T lymphocytes was established.
After immunization with allergen, specific IgE levels in hu-PBL-SCID sera were comparable with levels in donor sera. Although the majority of lymphocytes remained in the peritoneum, significant numbers of T lymphocytes were located in the spleen, where human IL-4, IL-5, and IFN-gamma messenger RNA expression was detected after stimulation with PHA and phorbol myristate acetate. Failure to induce cytokine production by human T lymphocytes isolated from the peritoneum and spleen of hu-PBL-SCID mice by allergen was reversed by stimulating with allergen in the presence of exogenously added IL-2 and antigen-presenting cells (APC), particularly CD14(+) monocytes. Under these conditions, allergen-reactive T cells expressed a T(H)2-like phenotype.
These data suggest that, after initial activation and induction of antibody production, human T lymphocytes enter a state of unresponsiveness, arising from a loss of human professional APC, in hu-PBL-SCID mice. The use of hu-PBL-SCID mouse models in studies on therapeutic approaches for allergy may benefit from the additional transfer of human professional APC.
通过转移特应性个体的外周血单个核细胞(PBMC)产生的人源化外周血淋巴细胞-重症联合免疫缺陷(Hu-PBL-SCID)小鼠,可能为研究人类对过敏原的反应及免疫治疗的潜在方法提供一种生理性体内模型。
本研究旨在调查从Hu-PBL-SCID小鼠分离的人过敏原反应性T淋巴细胞的功能活性和细胞因子谱。
将过敏个体的PBMC与过敏原共同注射到SCID小鼠体内。通过逆转录聚合酶链反应(RT-PCR)和免疫组织化学确定人淋巴细胞迁移和表型,测定血清中IgE水平,并确定产生过敏原反应性细胞因子的T淋巴细胞频率。
用过敏原免疫后,Hu-PBL-SCID血清中的特异性IgE水平与供体血清中的水平相当。虽然大多数淋巴细胞仍留在腹膜中,但大量T淋巴细胞位于脾脏中,在用PHA和佛波酯肉豆蔻酸酯刺激后,在脾脏中检测到人类白细胞介素-4(IL-4)、白细胞介素-5(IL-5)和干扰素-γ(IFN-γ)信使核糖核酸(mRNA)表达。通过在添加外源性IL-2和抗原呈递细胞(APC),特别是CD14(+)单核细胞的情况下用过敏原刺激,可逆转从Hu-PBL-SCID小鼠腹膜和脾脏分离的人T淋巴细胞不能被过敏原诱导产生细胞因子的情况。在这些条件下,过敏原反应性T细胞表达类似辅助性T细胞2(TH2)的表型。
这些数据表明,在初次激活和诱导抗体产生后,人T淋巴细胞进入无反应状态,这是由于Hu-PBL-SCID小鼠中人类专职APC的丧失所致。在过敏治疗方法研究中使用Hu-PBL-SCID小鼠模型可能受益于额外转移人类专职APC。